The Exposure to Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drugs in Pregnancy and Lactation

Overview

Journal Postepy Dermatol Alergol

Publisher Termedia

Specialty Allergy & Immunology

Date 2020 Aug 11

PMID 32774212

Citations 5

Authors

Alicja Goralczyk

Katarzyna Kolossa

Marzena Waszczak-Jeka

Rafal Adamczak

Slawomir Jeka

Affiliations

Soon will be listed here.

Abstract

Chronic inflammatory diseases often affect women of childbearing age. Since biologic and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) are more available, their use during conception, pregnancy and lactation has become a matter of concern. Current studies prove the safety of innovative therapy in pregnant women and may contribute to its wider use than before in pregnancy and lactation. It mainly concerns tumour necrosis factor α (TNF-α) inhibitors. We searched PubMed using Medical Subject Headings (MeSH) terms and identified relevant studies and guidelines. We present up-to-date knowledge of bDMARDs and tsDMARDs safety in pregnant and breastfeeding women.

Citing Articles

Placental transfer of tofacitinib in the dual-side human placenta perfusion model.

Eliesen G, Fransen M, Van Hove H, van den Broek P, Greupink R Curr Res Toxicol. 2024; 6:100149.

PMID: 38292667 PMC: 10825226. DOI: 10.1016/j.crtox.2024.100149.

BAFF and APRIL counterregulate susceptibility to inflammation-induced preterm birth.

Doll J, Moreno-Fernandez M, Stankiewicz T, Wayland J, Wilburn A, Weinhaus B Cell Rep. 2023; 42(4):112352.

PMID: 37027297 PMC: 10551044. DOI: 10.1016/j.celrep.2023.112352.

Progesterone-induced blocking factor 1 and cytokine profile of follicular fluid of infertile women qualified to in vitro fertilization: The influence on fetus development and pregnancy outcome.

Adamczak R, Ukleja-Sokolowska N, Lis K, Bartuzi Z, Dubiel M Int J Immunopathol Pharmacol. 2022; 36:3946320221111134.

PMID: 35861194 PMC: 9310294. DOI: 10.1177/03946320221111134.

Function of Follicular Cytokines: Roles Played during Maturation, Development and Implantation of Embryo.

Adamczak R, Ukleja-Sokolowska N, Lis K, Dubiel M Medicina (Kaunas). 2021; 57(11).

PMID: 34833469 PMC: 8625323. DOI: 10.3390/medicina57111251.

Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review.

Thatiparthi A, Martin A, Liu J, Egeberg A, Wu J Am J Clin Dermatol. 2021; 22(4):425-442.

PMID: 33861409 PMC: 8051287. DOI: 10.1007/s40257-021-00603-w.

References

Norgaard M, Larsson H, Pedersen L, Granath F, Askling J, Kieler H . Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study. J Intern Med. 2010; 268(4):329-37. DOI: 10.1111/j.1365-2796.2010.02239.x. View

Danve A, Perry L, Deodhar A . Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report. Semin Arthritis Rheum. 2014; 44(2):195-7. DOI: 10.1016/j.semarthrit.2014.05.006. View

Saito J, Yakuwa N, Takai C, Nakajima K, Kaneko K, Goto M . Tocilizumab concentrations in maternal serum and breast milk during breastfeeding and a safety assessment in infants: a case study. Rheumatology (Oxford). 2018; 57(8):1499-1501. DOI: 10.1093/rheumatology/key091. View

Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D . Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep. 2013; 6(4):105-7. PMC: 3543855. DOI: 10.3315/jdcr.2012.1116. View

Clarke D, Hilbish K, Waters D, Newcomb D, Chellman G . Assessment of ixekizumab, an interleukin-17A monoclonal antibody, for potential effects on reproduction and development, including immune system function, in cynomolgus monkeys. Reprod Toxicol. 2015; 58:160-73. DOI: 10.1016/j.reprotox.2015.10.008. View

Clowse M, Forger F, Hwang C, Thorp J, Dolhain R, van Tubergen A . Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017; 76(11):1890-1896. PMC: 5705850. DOI: 10.1136/annrheumdis-2017-211384. View

Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K . BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford). 2016; 55(9):1693-7. DOI: 10.1093/rheumatology/kev404. View

Brouwer J, Hazes J, Laven J, Dolhain R . Fertility in women with rheumatoid arthritis: influence of disease activity and medication. Ann Rheum Dis. 2014; 74(10):1836-41. DOI: 10.1136/annrheumdis-2014-205383. View

Rowan C, Cullen G, Mulcahy H, Keegan D, Byrne K, Murphy D . Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation. J Crohns Colitis. 2017; 12(3):376-378. DOI: 10.1093/ecco-jcc/jjx141. View

10.

de Man Y, Hazes J, van der Heide H, Willemsen S, de Groot C, Steegers E . Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum. 2009; 60(11):3196-206. DOI: 10.1002/art.24914. View

11.

Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A . Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2013; 43:78-84. DOI: 10.1016/j.reprotox.2013.11.004. View

12.

Onalan G, Tohma Y, Zeyneloglu H . Effect of Etanercept on the Success of Assisted Reproductive Technology in Patients with Endometrioma. Gynecol Obstet Invest. 2017; 83(4):358-364. DOI: 10.1159/000484895. View

13.

Mariette X, Forger F, Abraham B, Flynn A, Molto A, Flipo R . Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2017; 77(2):228-233. PMC: 5867410. DOI: 10.1136/annrheumdis-2017-212196. View

14.

Aljary H, Czuzoj-Shulman N, Spence A, Abenhaim H . Pregnancy outcomes in women with rheumatoid arthritis: a retrospective population-based cohort study. J Matern Fetal Neonatal Med. 2018; 33(4):618-624. DOI: 10.1080/14767058.2018.1498835. View

15.

Chakravarty E, Murray E, Kelman A, Farmer P . Pregnancy outcomes after maternal exposure to rituximab. Blood. 2010; 117(5):1499-506. DOI: 10.1182/blood-2010-07-295444. View

16.

Nakajima K, Watanabe O, Mochizuki M, Nakasone A, Ishizuka N, Murashima A . Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan. Mod Rheumatol. 2016; 26(5):667-71. PMC: 5020345. DOI: 10.3109/14397595.2016.1147405. View

17.

Skorpen C, Lydersen S, Gilboe I, Skomsvoll J, Salvesen K, Palm O . Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study. Ann Rheum Dis. 2017; 77(2):264-269. DOI: 10.1136/annrheumdis-2017-211641. View

18.

Mouyis M, Thornton C, Williams D, Giles I . Pregnancy Outcomes in Patients with Psoriatic Arthritis. J Rheumatol. 2017; 44(1):128-129. DOI: 10.3899/jrheum.160929. View

19.

Tsao N, Sayre E, Hanley G, Sadatsafavi M, Lynd L, Marra C . Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study. Ann Rheum Dis. 2018; 77(6):869-874. DOI: 10.1136/annrheumdis-2018-213023. View

20.

Tsao N, Lynd L, Sadatsafavi M, Hanley G, De Vera M . Patterns of Biologics Utilization and Discontinuation Before and During Pregnancy in Women With Autoimmune Diseases: A Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2017; 70(7):979-986. DOI: 10.1002/acr.23434. View